Company launches Time to Evolve campaign to equip surgeons and hospital systems with tools and resources to support their evolution to less invasive surgical techniques
SAN DIEGO – July 22, 2020 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today launched its Time to Evolve campaign, calling surgeons to reconsider the way patient care is delivered in spine surgery by adopting NuVasive’s less invasive approaches, best-in-class training and comprehensive procedural portfolio.
“With our 17 years of experience since pioneering XLIF, NuVasive remains the global leader in less invasive surgical techniques and is committed to providing surgeons with clinically proven and procedurally integrated offerings that disrupt the standard of spine care,” said Matt Link, president of NuVasive. “Our procedural approach resonates today more than ever as spine surgeons are facing pressure to be more efficient in the OR and enable better clinical outcomes for patients. Today, we call upon the spine industry to evolve and adopt less invasive spinal procedures to deliver better outcomes.”
NuVasive’s less invasive XLIF® procedure is clinically proven in more than 500 peer-reviewed articles, has been shown to provide better outcomes over traditional open spinal fusion and demonstrates benefits that align with the changing expectations of patients, surgeons, hospitals and payors, including;
- Improved clinical outcomes with fusion rates as high as 100 percent1 and up to 90 percent reduction in blood loss;2-5
- Reduced operative time by up to 15 percent, resulting in less time under anesthesia,6 and 50 percent shorter length of stay in the hospital;7 and
- Enhanced economics with up to 20 percent improved overall case efficiency and 10 percent reduction in hospital costs.7
NuVasive continues to innovate through access instrumentation and procedural components to improve spine care across a wide range of pathologies. Building on the legacy of XLIF, the Company launched X360®, a comprehensive approach to lateral single-position surgery that combines XLIF, XALIF™ and XFixation™. NuVasive’s other procedurally integrated solutions include maximum access surgery (MAS®) TLIF and MAS Midline, offering the benefits of less invasive surgery over traditional open posterior approaches.
“As a classically trained orthopedic spine surgeon with my current practice focused on trauma and complex spine surgery, I value the flexibility to treat patients with open and less invasive techniques,” said Dr. Steven Ludwig, orthopedic surgeon and professor of orthopedics at the University of Maryland Medical System in Baltimore, Maryland. “With the changing hospital environment, I’m equipped with a variety of procedurally integrated techniques that I have confidence will deliver the best outcomes for the hospital, surgeon and the patient.”
The Company’s procedural focus, paired with its clinical surgeon training program led by Clinical Professional Development (CPD), enables surgeons to confidently adopt new less invasive spine surgery techniques. CPD provides a variety of development courses focused on less invasive posterior and lateral techniques through targeted peer-to-peer engagement, interactive learning modules, cadaveric trainings and recently launched the Spine Surgery Evolved Webinar Series to provide further education on the benefits of less invasive surgery.
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company’s less invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company’s comprehensive procedural portfolio includes access, implants and fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in revenue, NuVasive has approximately 2,800 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
1Isaacs RE, Sembrano JN, Tohmeh AG, et al. Two-year comparative outcomes of MIS lateral and MIS transforaminal interbody fusion in the treatment of degenerative spondylolisthesis – Part 2: Radiographic findings. Spine 2016;41(8S):S133-S144.
2Dakwar E, Cardona RF, Smith DA, et al. Early outcomes and safety of the minimally invasive, lateral retroperitoneal transpsoas approach for adult degenerative scoliosis. Neurosurg Focus 2010;28(3):E8.
3Lehmen JA, Gerber EJ. MIS lateral spine surgery: a systematic literature review of complications, outcomes, and economics. Eur Spine J 2015;24(Suppl 3):S287-313.
4Dhall SS, Wang MY, Mummaneni PV. Clinical and radiographic comparison of mini-open transforaminal lumbar interbody fusion with open transforaminal lumbar interbody fusion in 42 patients with long-term follow-up. J Neurosurg Spine 2008;9(6):560-5.
5Whitecloud TS, Roesch WW, Ricciardi JE. Transforaminal interbody fusion versus anterior-posterior interbody fusion of the lumbar spine: a financial analysis. J Spinal Disord 2001;14(2):100-3.
6Sembrano JN, Tohmeh A, Isaacs R, et al. Two-year comparative outcomes of MIS lateral and MIS transforaminal interbody fusion in the treatment of degenerative spondylolisthesis: part I: clinical findings. Spine 2016;41(8 Suppl):S123-32.
7Lucio JC, VanConia RB, DeLuzio KJ, et al. Economics of less invasive spinal surgery: an analysis of hospital cost differences between open and minimally invasive instrumented spinal fusion procedures during the perioperative period. Risk Manag Healthc Policy 2012;5:65-74.